These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 17822458)
1. Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. Albouy B; Tourani JM; Allain P; Rolland F; Staerman F; Eschwege P; Pfister C BJU Int; 2007 Oct; 100(4):770-4. PubMed ID: 17822458 [TBL] [Abstract][Full Text] [Related]
2. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757 [TBL] [Abstract][Full Text] [Related]
3. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643 [TBL] [Abstract][Full Text] [Related]
4. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587 [TBL] [Abstract][Full Text] [Related]
5. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E; BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. Nayyar R; Sharma N; Gupta NP Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805 [TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Safarinejad MR Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502 [TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542 [TBL] [Abstract][Full Text] [Related]
17. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557 [TBL] [Abstract][Full Text] [Related]
18. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105 [TBL] [Abstract][Full Text] [Related]